Last reviewed · How we verify

Vonoprazan-Amoxicillin with Berberine

Nanjing First Hospital, Nanjing Medical University · FDA-approved active Small molecule

This combination uses vonoprazan to suppress gastric acid, amoxicillin to kill H. pylori bacteria, and berberine as an adjunctive antimicrobial and anti-inflammatory agent for H. pylori eradication.

This combination uses vonoprazan to suppress gastric acid, amoxicillin to kill H. pylori bacteria, and berberine as an adjunctive antimicrobial and anti-inflammatory agent for H. pylori eradication. Used for Helicobacter pylori infection eradication.

At a glance

Generic nameVonoprazan-Amoxicillin with Berberine
SponsorNanjing First Hospital, Nanjing Medical University
Drug classH. pylori eradication therapy (combination: proton pump inhibitor alternative + beta-lactam antibiotic + herbal antimicrobial)
TargetH+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); multiple H. pylori targets (berberine)
ModalitySmall molecule
Therapeutic areaGastroenterology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Vonoprazan is a potassium-competitive acid blocker that inhibits the H+/K+-ATPase pump to reduce gastric acid secretion, creating an optimal pH environment for amoxicillin efficacy against H. pylori. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis. Berberine, a plant alkaloid, provides additional antimicrobial activity against H. pylori and may enhance treatment efficacy through anti-inflammatory mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: